Dextropropoxyphene versus morphine
in opioid-naive cancer patients with pain
by
Mercadante S, Salvaggio L, Dardanoni G, Agnello A, Garofalo S
Department of Anesthesia and Intensive Care,
Buccheri La Ferla Fatebenefratelli Hospital,
Palermo,
Italy.
J Pain Symptom Manage 1998 Feb; 15(2):76-81

ABSTRACT

The role of opioids for moderate pain (so-called "weak" opioids) in the second step of the World Health Organization's analgesic ladder has been investigated in a prospective randomized study. Sixteen patients were administered dextropropoxyphene (DPP) in a dosage ranging from 120 mg to 240 mg daily (group 1), and 16 patients were administered the lowest doses (20 mg daily) of commercially available controlled-release morphine (group 2). Equianalgesic doses of oral morphine, pain relief, and symptoms during the first 10 days of therapy and during the last 4 weeks before death were assessed. Three of 16 patients maintained DPP until death, whereas three patients in group 2 were switched to DPP due to the occurrence of intolerable side effects. Intensity and frequency of nausea and vomiting, drowsiness, and dry mouth were higher in group 2 than in group 1 during the initial treatment. These results stress the role of "weak" opioids during the induction of opioid therapy in opioid-naive cancer patients.

Pain
Arousal
Morphine
Tramadol
Naloxone
Nociceptin
Sufentanil
Oxycodone
Carfentanil
Endomorphins
Novelty and pain
Dihydroetorphine
Fentanyl and ketamine
Opioids and anaesthesia
Opioids, mood and cognition
Propoxyphene (Darvon) : structure
Dextropopoxyphene for postoperative pain
Propoxyphene (dextropropoxyphene): review
Popoxyphene (Darvon) subjective and physiological effects

Refs
and further reading

HOME
HedWeb
Nootropics
cocaine.wiki
Future Opioids
BLTC Research
MDMA/Ecstasy
Superhapiness?
Utopian Surgery?
The Abolitionist Project
The Hedonistic Imperative
The Reproductive Revolution
Critique of Huxley's Brave New World

The Good Drug Guide
The Responsible Parent's Guide
To Healthy Mood Boosters For All The Family